What Are the Long-Term Effects of Nortriptyline?

Nortriptyline, a tricyclic antidepressant prescribed for depression, chronic pain, and several other conditions, carries a mix of sustained therapeutic benefits and gradual physical changes when taken over months or years. Some of these long-term effects are intentional and welcome, like continued protection against depressive relapse, while others creep up quietly, from steady weight gain to shifts in sleep patterns and heart rhythm. The balance between benefit and burden depends heavily on the person taking it, their age, their genetics, and what they are being treated for.

How Well Does It Prevent Depression From Coming Back?

For people who have recovered from a depressive episode, the main reason to stay on nortriptyline long-term is to keep the depression from returning. A landmark trial in adults over 59 with recurrent major depression found that nortriptyline, whether alone or combined with psychotherapy, was significantly better than placebo at preventing new episodes. The strongest results came from the combination: roughly 80% of patients receiving both nortriptyline and interpersonal psychotherapy stayed depression-free over the maintenance period.¹

A separate three-year study looked at what happens when you keep nortriptyline blood levels within a therapeutic window over an extended period. Even under those conditions, recurrence was not rare: about 29% of patients maintained at higher plasma levels and 40% at lower levels experienced a new depressive episode, with most recurrences happening in the first year.² That roughly one-in-three recurrence rate, even on active medication, is a useful reality check: nortriptyline reduces risk but does not eliminate it.

In elderly patients specifically, an 18-month follow-up comparing nortriptyline with the SSRI paroxetine found similar relapse rates for both drugs (about 10% for nortriptyline versus 16% for paroxetine), with nortriptyline-treated patients actually carrying a lower burden of residual depressive symptoms and side effects during that maintenance phase.³ So for long-term depression management, the drug holds up reasonably well, though it works best as part of a broader treatment plan.

Gradual Weight Gain

Weight gain is one of the most common reasons people eventually stop taking tricyclic antidepressants, and nortriptyline is no exception. A study tracking depressed outpatients on low-to-moderate doses of tricyclics, including nortriptyline at up to 50 mg per day, found a steady increase of roughly 1.3 to 2.9 pounds per month. Over the course of treatment, total weight gain ranged from about 3 to 16 pounds depending on the drug, dose, and how long it was taken. The gain was linear, meaning it did not plateau; it kept climbing the longer people stayed on the medication. Patients also reported a marked increase in craving for sweets. Ultimately, excessive weight gain led half the patients to stop treatment altogether, and those who did stop saw significant weight loss afterward.⁴

A larger analysis looking specifically at nortriptyline found more modest but still meaningful numbers: an average gain of about 1.2 kilograms (roughly 2.7 pounds) over the first 12 weeks, reaching about 1.8 kilograms (4 pounds) by six months. Nearly 39% of people on nortriptyline gained at least 2 kilograms over six months, while only about 2% lost that much. A smaller group, around 6%, gained 5 kilograms or more.⁵ The weight gain is not dramatic month to month, which is exactly why it sneaks up on people. Over a year or two, a few pounds per month adds up to a significant change that can affect self-image, metabolic health, and willingness to keep taking the drug.

Heart Rhythm and Cardiovascular Concerns

Tricyclic antidepressants as a class have long been associated with cardiac effects, and nortriptyline is included in that concern. The drug can alter the electrical activity of the heart, specifically by prolonging the QT interval, which is the time it takes for the heart’s lower chambers to recharge between beats. Animal research has shown that nortriptyline changes the ventricular repolarization process and can, in overdose situations, suppress potassium channels in heart muscle cells, leading to dangerous rhythm disturbances.⁶

At therapeutic doses and under normal use, the risk of a life-threatening arrhythmia is low for most people. But the concern is real enough that prescribers typically check an electrocardiogram before starting the drug, especially in older adults or anyone with existing heart conditions. For long-term users, periodic cardiac monitoring is standard practice. The cardiovascular risk profile is one of the main reasons newer antidepressants, which are much less likely to affect heart rhythm, are often tried first.

Changes to Sleep Architecture

Nortriptyline reshapes the structure of sleep in ways that persist as long as you take it. A longitudinal study in elderly depressed patients showed that the drug quickly and durably suppresses REM sleep, the dream-heavy phase of the sleep cycle, while simultaneously increasing phasic REM activity (the bursts of eye movement that occur during whatever REM sleep remains). These effects did not fade with continued use; they were still present well into maintenance treatment.⁷

An interesting secondary finding from the same research was that nortriptyline decreased sleep apnea episodes but had no effect on periodic limb movements during sleep. For someone who happens to have mild sleep apnea alongside depression, this could be an incidental benefit. For others, the ongoing suppression of REM sleep raises questions about whether long-term use might affect memory consolidation or emotional processing, since REM sleep is thought to play a role in both. In practice, many people on nortriptyline report vivid or unusual dreams, likely reflecting the altered REM dynamics.

Memory and Cognitive Effects

Nortriptyline’s anticholinergic properties, meaning it blocks a neurotransmitter involved in learning and attention, can affect memory over time. A study of recovered elderly depressed patients found that nortriptyline impaired immediate free recall on a memory test: performance dropped during learning trials compared to placebo, though delayed recall was less affected. When the drug was discontinued, patients showed measurable improvement on a set of memory self-assessment items, suggesting that the cognitive blunting was drug-related rather than a lingering effect of depression itself.⁸

This is a genuine trade-off for long-term users, particularly older adults. The anticholinergic burden from nortriptyline contributes to the “foggy” feeling some patients describe, including difficulty finding words, slower mental processing, and trouble with short-term retention. While nortriptyline has a lighter anticholinergic load than its parent compound amitriptyline, it is still meaningfully higher than what you would get from an SSRI or SNRI. For someone already worried about age-related cognitive decline, this matters.

Falls, Fractures, and Syncope in Older Adults

A large retrospective study in Southern California compared nortriptyline with several other antidepressants and pain medications in older adults and found something that may surprise people who assume all antidepressants carry the same fall risk. Using nortriptyline as the reference point, nearly every other antidepressant studied was associated with a higher risk of falls. Paroxetine, fluoxetine, sertraline, citalopram, venlafaxine, duloxetine, and escitalopram all showed significantly elevated fall risk compared to nortriptyline, with adjusted hazard ratios ranging from about 1.2 to 1.6. Only gabapentin showed a similar fall risk.⁹

The fracture picture was similarly favorable for nortriptyline: hazard ratios for fractures were significantly higher for paroxetine, venlafaxine, duloxetine, fluoxetine, sertraline, citalopram, escitalopram, and gabapentin compared to nortriptyline, with amitriptyline being the only drug in the comparison with a statistically similar fracture risk. Syncope, or fainting, also tended to be less common with nortriptyline than with several SSRIs and SNRIs.⁹

This finding runs counter to a common clinical assumption that tricyclics are inherently more dangerous for older adults than newer drugs. It does not mean nortriptyline is risk-free in this population, but it does suggest the comparative risk profile is more nuanced than the blanket warnings imply.

What Happens to Your Eyes

The anticholinergic activity in nortriptyline can affect the eyes over time, particularly the drainage angle inside the eye where fluid exits. A study comparing patients on long-term anticholinergic psychotropic drugs, including tricyclic antidepressants, with those on non-anticholinergic medications found that the anticholinergic group had significantly narrower drainage angles on both clinical examination and imaging. The scleral spur angle, a measurement of how open the drainage pathway is, was meaningfully smaller in the anticholinergic group. However, actual intraocular pressure was not significantly different between groups.¹⁰

In practical terms, this means long-term nortriptyline use can gradually narrow the angle through which your eye drains fluid, even if your eye pressure stays normal for now. For someone who already has narrow angles or a family history of angle-closure glaucoma, this is worth monitoring. Routine eye exams become more important the longer you stay on the drug, and you should mention nortriptyline to your ophthalmologist or optometrist so they can check specifically for angle narrowing.

Bone Density

There is a broader concern, supported by systematic review evidence, that antidepressant use in general is linked to bone loss over time.¹¹ Most of the research attention on this topic has focused on SSRIs, which appear to have a clearer effect on serotonin signaling in bone cells. Nortriptyline’s contribution to bone loss is less well isolated in the literature, but given that tricyclics share some serotonergic activity and that long-term users are often older adults already at risk for osteoporosis, the concern is not trivial. If you are on nortriptyline for years, discussing bone density screening with your doctor is reasonable, especially if you have other risk factors like low body weight, smoking, or a sedentary lifestyle.

Long-Term Use for Pain

Nortriptyline is commonly prescribed off-label for neuropathic pain conditions like diabetic neuropathy, post-herpetic neuralgia (the pain that lingers after shingles), and fibromyalgia. The evidence base for this use, however, is thinner than many prescribers acknowledge. A Cochrane systematic review examining nortriptyline for neuropathic pain found little evidence to support its use, noting that the available studies were small, methodologically flawed, and susceptible to major bias. The review did not find evidence supporting nortriptyline as a first-line treatment for neuropathic pain.¹²

That said, a more recent comparative meta-analysis suggested nortriptyline can produce meaningful pain reduction in specific conditions like post-herpetic neuralgia, painful diabetic neuropathy, and fibromyalgia, while being better tolerated than amitriptyline, a closely related tricyclic that is often the default choice.¹³ The practical takeaway is that nortriptyline may work well enough for pain for individual patients, but the evidence behind it is weaker than for many other pain medications, and long-term use for this purpose means accepting the full range of side effects described throughout this article for a benefit that is less robustly proven.

Why the Same Dose Affects People Differently

One of the more frustrating aspects of taking nortriptyline long-term is that the same dose can produce wildly different blood levels in different people. This is largely driven by genetics, specifically variations in the liver enzyme CYP2D6 that metabolizes the drug. Some people break it down quickly and may never reach a therapeutic level on a standard dose, while others metabolize it so slowly that a normal dose produces dangerously high blood concentrations.

Recent research has shown that using genetic testing to guide nortriptyline dosing significantly increases the likelihood of reaching therapeutic blood levels compared to standard one-size-fits-all dosing, while also reducing the variability in how much drug ends up in the bloodstream.¹⁴ For long-term users, this has real implications. If you have been taking nortriptyline for months and find it either ineffective or loaded with side effects, pharmacogenetic testing can reveal whether you are getting too little or too much of the active drug. It is not yet routine practice everywhere, but it is increasingly available and can save months of trial-and-error dose adjustments.

Pregnancy and the Next Generation

For people of childbearing age on long-term nortriptyline, questions about pregnancy are inevitable. A large register-based cohort study looked at whether children born to mothers who continued antidepressants during pregnancy had a higher risk of developing affective disorders (conditions like depression and bipolar disorder) later in life. Children of mothers who continued antidepressants during pregnancy did show a modestly elevated risk, with a hazard ratio of about 1.20 compared to children of mothers who stopped before pregnancy. However, the same study found a similar elevation in risk among children whose fathers continued antidepressants during the pregnancy period, with a hazard ratio of about 1.29. Since fathers do not contribute to intrauterine drug exposure, this pattern suggests that the increased risk in children is more likely driven by the parents’ underlying mental health conditions rather than direct fetal exposure to the drug itself.¹⁵

This finding does not eliminate all concern about taking nortriptyline during pregnancy. Tricyclics do cross the placenta, and neonatal withdrawal effects have been documented. But the father-control analysis is reassuring on the question of whether the drug itself programs long-term psychiatric risk in offspring. The decision about whether to continue nortriptyline during pregnancy involves weighing the risks of untreated depression (which are substantial and well-documented) against the more uncertain risks of fetal drug exposure, ideally with input from both a psychiatrist and an obstetrician.

Dry Mouth and Its Downstream Consequences

Dry mouth (xerostomia) is one of the most persistent anticholinergic side effects of nortriptyline, and while it sounds minor, its long-term consequences are anything but. Saliva protects teeth from decay, helps maintain healthy gum tissue, and aids in early-stage digestion. When saliva production is chronically reduced, the result over months and years can include accelerated tooth decay, increased risk of oral infections like thrush, difficulty swallowing, and chronic discomfort. Dentists sometimes see patients on long-term tricyclics who develop cavities at a rate that seems out of proportion to their oral hygiene habits, and chronic dry mouth is typically the culprit. If you are on nortriptyline indefinitely, mentioning it to your dentist allows them to recommend saliva substitutes, fluoride rinses, or more frequent cleanings to stay ahead of the damage.

Constipation follows a similar pattern: another anticholinergic effect that is easy to dismiss early on but can become a serious quality-of-life issue with chronic use. Long-term constipation can contribute to hemorrhoids, anal fissures, and in severe cases, fecal impaction, particularly in older adults who may already have slowed gut motility. Dietary adjustments and over-the-counter remedies usually manage it, but it requires ongoing attention rather than the one-time “it’ll get better as you adjust” reassurance that patients often receive at the start of treatment.